Fractyl Health announces the publication of a new pioneering model of the role of the intestine in metabolism


LEXINGTON, Mass .– (COMMERCIAL THREAD) – Fractyl Health, a life sciences company dedicated to the development of novel therapeutic interventions aimed at reversing the epidemic of metabolic diseases, including type 2 diabetes (T2DM), today announced the publication of a new innovative model of metabolism, the Metabolic Balance Model.

The study synthesizes several existing streams of evidence from molecular biology through clinical observations to build a new paradigm for understanding the role of the small intestine in metabolic disease. The company believes that the Metabolic Balance Model is one of the most comprehensive frameworks in this area. The metabolic balance model identifies the proximal small intestine as an important target and highlights the key role it plays in nutrient detection and signaling, and the critical importance of the relationship between the proximal small intestine and distal in establishing the balance necessary to remain metabolically healthy. Diets high in easily digestible fats and sugars have been believed to cause an overgrowth of the proximal small intestine lining, which can lead to an imbalance in nutrient sensing and signaling between the proximal and distal small intestine. It was this imbalance, which caught the attention of the founders of Fractyl Health, which then led the company to seek therapeutic approaches that could correct hormonal signals in the gut and stem the tide of metabolic disease in the gut. the society.

“Over the past three months, we have seen several publications from leading scientists who provide important understanding of the pathology of the intestinal lining caused by diets high in fat and sugar leading to metabolic diseases. We are delighted to have partnered with some of the foremost experts in type 2 diabetes research to produce this new paradigm for understanding the causal mechanism linking these gut changes to metabolic disease, based on pioneering research from Fractyl Health. and others, ”said Harith Rajagopalan, MD, Ph.D., co-founder and CEO of Fractyl Health and lead author of the article. “It is necessary to take a new look at how we might correct the imbalance in the gut if we are to make a real difference in the lives of patients. ”

“I have spent my career trying to better understand the mechanisms underlying metabolic diseases in the body. The knowledge gained over the past 10 years has enabled us to reframe our understanding and elevate the role of the gut as an essential regulator of metabolism, ”said Alan Cherrington, Ph.D., Professor of Medicine, Jacquelyn A. Turner and Dr. Dorothy J. Turner Chair in Diabetes Research, Vanderbilt University School of Medicine, and one of the authors of the article. “What’s exciting to me is that we now have a model to understand the role of the gut that allows us to imagine how to potentially reverse metabolic disease by targeting this critical organ.

The article, titled “A Gut-Centric Model of Metabolic Homeostasis”, is published in the October issue of Diabetes Science and Technology Journal.

About Fractyl Health

Fractyl Health is dedicated to the development of new treatments for metabolic diseases based on innovative scientific knowledge on the root causes of metabolic dysfunction. Fractyl Health’s lead product candidate, the Revita DMR System, is designed to be an ambulatory endoscopic procedure for thermal ablation of the duodenal mucosa to improve glycemic control and eliminate insulin requirements in patients with T2DM that are insufficiently controlled by long-acting insulin. The company’s findings hold the potential to treat other metabolic diseases in the future, including non-alcoholic fatty liver disease / non-alcoholic steatohepatitis (NAFLD / NASH), with the goal of potentially reducing the global economic and health burden of diseases. metabolic. Fractyl Health is a privately held life sciences company based in Lexington, Mass. For more information, visit or

Source link


Leave A Reply